Press Release 2017 - Sami-Sabinsa Group | Formerly Known as Sami Labs Limited

Disclaimer

US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.

Sabinsa’s Curcumin C3 Complex® and Aspirin Combination Researched in Groundbreaking Colorectal Cancer Study

Sami-Sabinsa Group Opens 2nd Continuous Extraction Facility to Meet Demand for Curcumin C3 Complex® and Other Extracts

Sabinsa to Launch Promond™ Almond Protein Powder, Give Away New BioPerine® Book at Supplyside West

Sabinsa Granted US Patent for Synbiotic Composition of LactoSpore® Shelf Stable Probiotic and Cranberry Fibers

New Patents Granted to Sabinsa’s Cosmetics Division in US and EU

Sabinsa Publishes Scientific Compendium on BioPerine® Black Pepper Extract

About

Certificates

Global Contacts List

Get in Touch

Press Releases 2017